Swiss Industrial Giants ABB and Novartis Target US for Major Investments

The economic compass of Switzerland’s industrial heavyweights is pointing undeniably West. In a coordinated display of confidence, both ABB and Novartis are doubling down on the United States, signaling a massive capital flight toward American dynamism. This isn't just a gentle pivot; it is a seismic shift in strategy. With ABB identifying the US as its "maximum growth" market and Novartis breaking ground on a colossal hub in San Diego, the message is crystal clear: the future of Swiss industrial growth is being built on American foundations.

While Europe grapples with stagnation, Swiss multinationals are aggressively pursuing the lucrative, fast-paced American market. The sheer scale of these moves—billions in committed capital and thousands of high-tech jobs—underscores a new reality where the Atlantic Ocean is becoming a bridge for Swiss innovation rather than a barrier. As geopolitical tides shift, these corporate giants are not waiting for permission; they are planting their flags where the returns are highest.

ABB is firing on all cylinders, and its fuel source is unmistakably American. The Zurich-based engineering giant just closed the 2025 financial year with a staggering 20% jump in net profit, hitting $4.7 billion. CEO Morten Wierod is not mincing words about the driver of this success: "That is where the greatest growth has occurred in recent years and this trend continues," he declared, referring to the US market.

The numbers back the narrative. With sales climbing 7% to $33.2 billion and operating margins widening to a robust 19%, ABB is capitalizing on a booming demand for electrification and automation in the States. While the company maintains a presence in Asia and Europe, the strategic priority is clear. Wierod explicitly ranked the Americas as the top priority, leaving Europe in a distant third place. Investors have roared their approval, driving ABB stock up 169% over the last five years, proving that a US-centric strategy is paying dividends for Swiss shareholders.

If ABB is electrifying America, Novartis is rewriting its genetic code. The pharma giant has initiated a breathtaking $23 billion investment plan across the US over the next five years, a figure that dwarfs typical industrial expansions. The centerpiece of this offensive is a new 43,300 square meter biomedical research center in San Diego, set to open in 2029. This isn't just a building; it's a fortress of innovation that will house 1,000 top-tier researchers.

Fiona Marshall, President of Novartis Biomedical Research, asserts that this facility will "accelerate drug discovery for patients around the world." By integrating advanced artificial intelligence into every stage of research, Novartis is aiming to revolutionize treatments in neuroscience, oncology, and regenerative medicine. This move follows intense pressure from US administrations to localize production, but Novartis has turned political necessity into a strategic advantage, embedding itself deeply into the Californian biotech ecosystem.

The contrast could not be more stark: while billions flow into US infrastructure, Europe is being relegated to maintenance mode. ABB’s Wierod was brutally honest in his assessment, noting that in Europe, the focus is merely on "improving the efficiency of existing plants," with absolutely no plans for new large-scale factories. The "Old Continent" is viewed as lacklustre, trapped by slow growth and geopolitical inertia.

This divergence poses a critical question for the Swiss economy. While Swiss companies thrive globally, their domestic and European footprints are becoming static. The dynamic growth, the new jobs, and the cutting-edge facilities are increasingly exported to Texas, California, and North Carolina. As Swiss industrial giants reassess their supply chains in a volatile world, the United States offers a safe, high-growth harbor that Europe currently fails to provide. For now, the verdict from the boardroom is final: America is where the action is.